Financial Results for Q2 FY2017(April 1 to September 30,2017)

from the beginning

Financial Results for Q2 FY2017 (April 1 to September 30, 2017)

Financial Results for Q2 FY2017

• Financial Results for Q2 FY2017

• Sales of Major Products in Japan

• Sales of Major Products in North America & China

• Segment Information

• Ordinary income & Net income attributable to owners of the parent

Financial Forecasts for FY2017

• Financial Forecasts for FY2017

• Segment Information

To strengthen robust revenue base

• Pursue Operational Efficiency in Japan

• Strengthen Robust Revenue Base in the U.S.

Research & Clinical Development Status

• Reorganization of Research Framework (October 2017)

• Clinical Development Updates: Psychiatry & Neurology Area

• Clinical Development Updates: Oncology Area

• Clinical Development Updates: Other Areas (Diabetes)

• Clinical Development Updates: Regenerative Medicine/Cell Therapy

• Other topics

• Submission Target of Key Late-stage Pipeline (as of October 2017)

Appendices

• Changes from Q2 FY2016

• Net Sales by Segment

• Financial Position / Cash Flows

• Sales of Major Products in Japan

• Sales of Major Products in North America & China

• Segment Information FY2017 / FY2016

• Development Pipeline(1) (Psychiatry & Neurology Area)(as of October 30, 2017)

• Development Pipeline(2) (Oncology Area)(as of October 30, 2017)

• Development Pipeline(3) (Oncology & Other Areas)(as of October 30, 2017)

• Napabucasin - Clinical development progress (as of October 30, 2017)

• Amcasertib, Napabucasin - Clinical development progress (as of October 30, 2017)

• Napabucasin Phase 1b/2 study (Colorectal Cancer: 246 study)

• Napabucasin Phase 1b/2 study (Pancreatic Cancer: 118 study)

• LATUDA(R) (lurasidone) - Clinical development progress (as of October 30, 2017)

• Product Launch Plan (as of October 2017)

• Regenerative Medicine/Cell Therapy Business Plan (as of October 2017)

• Disclaimer Regarding Forward-looking Statements

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8